Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the re-investment of dividends paid on April 8, 2010.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share purchase transactions:
- Ordinary shares purchase price: £12.79 per share (April 15, 2010).
- Ordinary share ADRs purchase price: $39.29 per ADR (April 8, 2010).
Material Changes
The filing details an increase in share interests for various executives following dividend re-investment. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the specific number of shares and ADRs acquired by each listed executive (e.g., Mr. A P Witty, Mr. J S Heslop) to confirm total holdings.
- Confirm the dividend re-investment plan terms applicable to the April 8, 2010 payment.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial results.